# Can ARA-290 reduce age-related cardiac inflammation and frailty?

Canonical source: https://retacompare.com/research/can-ara-290-reduce-age-related-cardiac-inflammation-and-frailty

Peptide Longevity Q&A · 2022-01-01


    Research indicates that ARA-290 significantly reduces age-related cardiac inflammation and mitigates declines in heart function, ultimately leading to a decrease in frailty in aged rats. This peptide enhances cardiomyocyte health and preserves overall healthspan by addressing inflammation and tissue remodeling.

 What the research shows

The study investigated the effects of ARA-290, an 11-amino acid peptide derived from erythropoietin, on age-related cardiac changes in Fischer 344 x Brown Norway rats. The research involved a randomized controlled trial with 48 rats, aged 18 months, over a period of 15 months, during which the subjects received either chronic ARA-290 treatment or saline. Key measurements included serial echocardiography, tail blood pressure, body weight, and a frailty index calculated at 33 months of age. Tissue samples were collected at 4-month intervals to assess inflammatory markers and cardiac remodeling, while mitochondrial and myocardial cell health was evaluated in isolated left ventricular myocytes.

 Why it matters for longevity

The findings highlight the potential of ARA-290 to address significant aging-related issues, such as cardiac inflammation and frailty, which are common in older populations. By reducing inflammation and improving cardiac function, ARA-290 may contribute to an extended healthspan, allowing individuals to maintain better overall health and function as they age. The preservation of cardiac health is crucial for longevity, as heart function is integral to overall vitality and well-being in older adults.

 Key findings at a glance

ARA-290 treatment reduced age-related increases in cardiac inflammation and fibrosis.

The peptide improved mitochondrial health in cardiomyocytes.

ARA-290 preserved left ventricular ejection fraction and reduced blood pressure elevations associated with aging.

Chronic treatment led to a significant decrease in markers of frailty by the end of the study.

Increased autophagy flux and reduced cellular lipofuscin accumulation were observed in treated subjects.

 How ARA-290 works (background)

ARA-290, also known as cibinetide, operates through mechanisms that reduce inflammation and fibrosis in cardiac tissues. By targeting pathways involved in the inflammatory response, ARA-290 decreases the levels of pro-inflammatory cytokines and attenuates the activation of NF-κB, a key regulator of inflammation. Additionally, the peptide enhances autophagy in cardiomyocytes, promoting the removal of damaged cellular components and improving overall cell health. This multifaceted approach helps mitigate the structural and functional declines commonly associated with aging.

 Safety, caveats, and what we don't yet know

While the research provides promising insights into the effects of ARA-290 on cardiac health and aging, it is essential to note that these findings are based on preclinical studies in animal models. Further research is necessary to determine the safety and efficacy of ARA-290 in human populations. Additionally, the long-term effects and potential side effects of ARA-290 treatment remain to be fully understood. Future studies should also explore the peptide's impact on other organ systems and its overall role in promoting longevity.

 Bottom line

ARA-290 has shown potential in reducing age-related cardiac inflammation and improving heart function, which may lead to a decrease in frailty and enhance healthspan in aging populations.

 Related questions

 Does ARA-290 improve mitochondrial function in aging tissues?

Research suggests that ARA-290 enhances mitochondrial health in cardiomyocytes, which is crucial for maintaining cellular function and energy production as tissues age.

 Can ARA-290 mitigate age-related frailty?

Yes, ARA-290 has been shown to significantly reduce markers of frailty in aged rats, indicating its potential role in promoting healthspan and longevity.

 What is the mechanism of action for ARA-290?

ARA-290 primarily works by reducing inflammation, enhancing autophagy, and improving mitochondrial health, which collectively contribute to better cardiac function in aging models.

 Source: PubMed · Front Cardiovasc Med · published 2022-01-01.

## Sources

- PubMed · Front Cardiovasc Med: https://pubmed.ncbi.nlm.nih.gov/36741836/